Press Release: The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia

The European Medicines Agency (EMEA), on 23 October 2008, recommended the suspension of the marketing authorisation for Acomplia (rimonobant) from Sanofi-Aventis. The EMEA Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Acomplia no longer outweigh its risks and the marketing authorisation should be supsended across the European Union.

• Primary Source

European Medicines Agency: Public statement on Acomplia (Rimonabant), 30.1.09 http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/3945709en.pdf

European Medicines Agency: Public statement on Zimulti (Rimonabant), 30.1.09 http://www.emea.europa.eu/humandocs/PDFs/EPAR/zimulti/3956009en.pdf

---